Short Courses*


SUNDAY, APRIL 24 (10:00am – 1:00pm)

Registration: 9:00am-5:00pm

SC2: Bioanalytical Considerations of Multi-Domain Biotherapeutics: Preclinical and Clinical Development - Detailed Agenda

Carol Gleason, MS, Principal Biostatistician, Bristol-Myers Squibb Co.

Yanchen Zhou, Ph.D., Scientist, Amgen Inc.

Darshana Jani, M.S., Senior Manager, Pfizer, Inc.

Priya Sriraman, Ph.D, Senior Principal Scientist, Non Clinical Safety, Celgene

Shannon D. Chilewski, MSc, Research Scientist II, Analytical and Bioanalytical Development, Bristol-Myers Squibb 

SC3: Antibody Humanization via One Hot Homology Model Workshop (Hands-On) - Detailed Agenda

Vinodh B. Kurella, Ph.D., Senior Scientist, Molecular Engineering Unit, Intrexon Corp.

SC4: Translational Considerations for Development of Monoclonal Antibodies: Focus on Early Discovery (Part I) - Detailed Agenda

Gadi Bornstein, Ph.D., Global Correlative Science Leader, Director, Novartis Pharmaceuticals

Randall Brezski, Ph.D., Scientist, Antibody Engineering, Genentech

Enrique Escandon, Ph.D., Senior Principal Scientist, DMPK and Disposition, Merck Research Laboratories

Vaishnavi Ganti, Ph.D., Senior Scientist, Biologics Discovery-DMPK, Merck Research Laboratories

Scott L. Klakamp, Ph.D., Vice President, Chemistry and Biochemistry, Bioptix

Mohammad Tabrizi, Ph.D., Head, Director & Senior Fellow, PKPD, Merck


SUNDAY, APRIL 24 (2:00 – 5:00pm)

 

SC6: In silico Immunogenicity Predictions (Hands-On) Workshop - Detailed Agenda

Vinodh B. Kurella, Ph.D., Senior Scientist, Molecular Engineering Unit, Intrexon Corp.

SC7: Translational Considerations for Development of Monoclonal Antibodies: Focus on Nonclinical Development to Clinic (Part II) - Detailed Agenda

Gadi Bornstein, Ph.D., Global Correlative Science Leader, Director, Novartis Pharmaceuticals

Randall Brezski, Ph.D., Scientist, Antibody Engineering, Genentech

Enrique Escandon, Ph.D., Senior Principal Scientist, DMPK and Disposition, Merck Research Laboratories

Vaishnavi Ganti, Ph.D., Senior Scientist, Biologics Discovery-DMPK, Merck Research Laboratories

Scott L. Klakamp, Ph.D., Vice President, Chemistry and Biochemistry, Bioptix

Mohammad Tabrizi, Ph.D., Head, Director & Senior Fellow, PKPD, Merck


TUESDAY, APRIL 26 (6:00pm-8:00pm)
DINNER

SC8: Next-Generation Sequencing of Antibody Libraries: Details on Experimental and Bioinformatic Methods - Detailed Agenda

Sai Reddy, Ph.D., Assistant Professor, Biosystems Science and Engineering, ETH Zurich, Switzerland

SC9: Overcoming the Challenges of Immunogenicity Assessment - Detailed Agenda

Jim McNally, Ph.D., Associate Director, PDM Immunogenicity Expert, EMD Serono

Valerie Theobald, Ph.D., Director, Bioanalytical Development, Shire

SC10: Analyzing and Rationalizing Protein-Protein Interactions - Detailed Agenda

Nels Thorsteinson, Scientific Services Manager, Biologics, Chemical Computing Group

Alain Ajamian, Ph.D., Director, Chemical Computing Group


THURSDAY, APRIL 28 (5:45pm-7:45pm)
DINNER

SC11: Clinical Prospects of Cancer Immunotherapy - Detailed Agenda

Gaurav Goel, M.D., Assistant Professor, Division of Medical Oncology, Medicine, University of Kentucky Markey Cancer Center

Weijing Sun, M.D., FACP, Professor, Medicine; Director, GI Cancers Section of Hematology-Oncology; Co-Director, GI Cancer Center of Excellence, Medicine/Hematology-Oncology, University of Pittsburgh School of Medicine

SC12: Strategic Bioassay Design and Analysis - Detailed Agenda

Liming Shi, MS, MA, Senior Group Leader, Bioassay Development, Hospira, a Pfizer Company

SC13: Critical Considerations for the Design and Development of Antibody-Drug Conjugates - Detailed Agenda

Mohammad Tabrizi, Ph.D., Head, Director & Senior Fellow, PKPD, Merck

Isabel Figueroa, Ph.D., Scientist, PTPK Department, Genentech

Shawn Owen, Ph.D., Assistant Professor, Pharmaceutical Chemistry, University of Utah


*Separate Registration Required